Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (RENSE)

This study has been terminated.
(Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.)
Sponsor:
Information provided by (Responsible Party):
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01104662
First received: April 2, 2010
Last updated: October 9, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)